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Introduction
The Heart Rhythm Society convened a research symposium on December 9–10, 2013, in 
Washington, DC, that focused on the prevention of atrial fibrillation (AF) as well as AF-
related stroke and morbidity. Attendees sought to summarize advances in understanding AF 
since a 2008 National Institutes of Health (NIH) conference on this topic1 and to identify 
continued knowledge gaps and current research priorities. The research symposium also 
sought to identify key deficiencies and opportunities in research infrastructure, operations, 
and methodologies. The committee sought to identify both basic research targets and how 
clinical AF research could be improved in the current health care environment. This 
whitepaper summarizes our deliberations in an effort to accelerate progress toward 
preventing AF and its consequences. Although largely focused on primary prevention of AF, 
the paper also addresses some aspects of secondary prevention of recurrent AF due to the 
continuum of risk factors that contribute to arrhythmogenesis, permissive left atrial (LA) 
substrates, and the emergence of AF.
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Scope of the problem
More than 33 million individuals worldwide have AF, and there are approximately 5 million 
new cases each year.2 AF incidence and prevalence increase with age; the prevalence of AF 
increases 3-fold between the 6th and 8th decade of life. The increasing frequency of AF is 
particularly notable in industrialized nations where the increment in AF is more than 2-fold 
greater than in developing nations.2 Based on estimates from the Framingham Study, the 
lifetime risk of developing AF has been estimated at 1 in 4.3 Accordingly, treatment of AF 
has been targeted as a top priority for comparative effectiveness research by the Institute of 
Medicine.4
AF leads to a 5-fold increased risk of stroke, a 2-fold risk of dementia, as well as increased 
risk of myocardial infarction, heart failure (HF), and death.5 Over the past 2 decades, 
hospital admissions for AF have increased by two-thirds. Direct expenditures related to AF 
cost Medicare at least $6 billion annually.5 In addition to higher morbidity and mortality, 
AF-related strokes are associated with 20% greater health care costs relative to non-AF 
strokes.6 Currently approved AF therapies are only partially effective and are associated 
with substantial morbidity and mortality. Whereas many studies have focused on the 
treatment of AF, relatively few have been directed at prevention of AF. In contrast to 
coronary heart disease and stroke, preventive strategies and therapies for AF remain 
unproven.1
Analysis of clinical practice guidelines reveals a gap between the need for evidence and its 
availability.7 Patients seek evidence-based guidance related to diet, exercise, and lifestyle 
for risk factor modification and AF prevention, but systematic studies in these areas are 
currently quite limited. More research is required to support evidence-based 
recommendations as part of a comprehensive approach to prevention and treatment of AF. 
Developing an evidence base from which we can adequately predict and prevent AF is an 
important public health goal.
Most trials are underpowered to answer clinically meaningful questions, and many critical 
trials funded by industry and the NIH are not published.8,9 These findings suggest that the 
clinical research enterprise lacks effective prioritization. There is currently no (1) consensus-
derived list of top priorities for research in AF nor (2) a systematic portfolio analysis 
focused on benefit to patients or providers. This manuscript seeks to begin to address these 
gaps.
Recent progress with respect to fundamental AF mechanisms, key 
knowledge gaps, and therapeutic opportunities Relation of atrial ectopy to 
development of AF
Frequent atrial ectopy (premature atrial contractions [PACs]) during 24-hour Holter 
recordings has been identified as a strong predictor of AF development, with discriminatory 
power similar to the Framingham risk score over 5 to 10 years of follow-up and even better 
at 15 years.10 Atrial ectopy has significant prognostic potential that may help to identify 
patients at greatest risk for AF and for whom early treatment may enable primary prevention 
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of AF. PAC frequency has been positively associated with age, height, and brain natriuretic 
peptide (BNP) levels; PAC frequency has been inversely related to HDL levels and physical 
activity.11 Studies testing the causal link(s) between PAC burden and incident AF are 
needed. Studies testing the hypothesis that early treatment in these patients is beneficial are 
also warranted, but the current lack of therapies that are both highly effective and safe 
remains an obstacle. Safety is a critical consideration in preventive medicine.12
Ectopy is a common trigger for AF initiation; frequent ectopy has been associated with both 
incident10 and postoperative AF.13 Ectopy arises from 3 general mechanisms: (1) atrial 
automaticity, (2) early afterdepolarizations (EADs), and (3) delayed afterdepolarizations 
(DADs). EADs and DADs are triggered activities that occur during and after action potential 
repolarization, respectively. Triggered activity can be caused by any condition that enhances 
net inward current (influx of Na+ or Ca2+ ions, relative to efflux of K+ ions).
AF represents an interaction between focal or triggered activity that initiates AF episodes 
and development of a “vulnerable substrate” critical for AF persistence.14 Reentry can result 
from altered electrical properties (a “functional substrate”) and may contribute to persistent 
AF. Functional reentry mechanisms include abbreviation of atrial refractoriness and/or 
slowed conduction allowing the impulse to reenter the circuit. Focal ectopy arising from the 
muscular sleeves encircling the pulmonary veins (PVs)15 often provokes paroxysmal atrial 
fibrillation (pAF) episodes, whereas functional and fixed substrates (ie, atrial scar) play 
increasing roles as AF becomes persistent and permanent, respectively.14 Persistent AF 
promotes both electrical remodeling (changes in ion channel expression or activity) and 
structural remodeling (interstitial fibrosis, myocyte hypertrophy, apoptosis, etc) of the atria.
Atrial sodium and calcium handling
Cardiac conduction is primarily attributable to the activity of voltage-gated Na+ channels 
(NaV1.5). Sodium current (INa) normally activates and then inactivates fully within a few 
milliseconds. During HF and in some cases of AF, delayed inactivation results in a 
persistent or “late” component of INa. Late INa hinders Ca2+ extrusion by the Na+/Ca2+ 
exchanger, altering intracellular Ca2+ regulation.
Many recent studies have revealed a critical role for calcium (Ca2+) handling abnormalities 
in the etiology of AF. Atrial myocytes isolated from cardiac surgery patients have shown 
that AF is associated with enhanced spontaneous Ca2+ release from intracellular stores in the 
sarcoplasmic reticulum (SR).16 In atrial myocytes from persistent AF patients, enhanced 
activity of Ca2+/calmodulin-dependent kinase II (CaMKII) has a central role in the 
dysregulation of intracellular Ca2+ handling.16 Although phosphorylation and activation of 
CaMKII are the normal responses to elevated cytosolic Ca2+ levels, pathologic CaMKII 
activation can result from several posttranslational modifications, including methionine 
oxidation.17 In persistent AF, the type 2 ryanodine receptor (RyR2), the primary 
intracellular Ca2+ release channel, is a major target of CaMKII.16 Increased RyR2 
phosphorylation by CaMKII promotes diastolic SR Ca2+ leak that can cause DADs. In 
persistent AF patients, CaMKII inhibitors normalized Ca2+ handling.16 Increased Protein 
kinase A (PKA) phosphorylation and reduced protein phosphatase activity may also 
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contribute to RyR2 dysfunction in AF.16 CaMKII-mediated calcium dysregulation in AF has 
been reviewed in a recent publication.17
Increased SR Ca2+ leak and spontaneous SR Ca2+ release events have also been found in 
studies of atrial myocytes from patients with pAF, but these events seem to be CaMKII 
independent because CaMKII autophosphorylation and RyR2 phosphorylation levels were 
unaltered.18 Because the tissue was harvested while atria were in sinus rhythm, it is 
unknown if CaMKII activation occurs during or immediately prior to pAF. Lower 
expression of junctophilin-2 (JPH2) relative to RyR2 has been proposed to promote RyR2-
mediated SR Ca2+ leak in pAF patients, as JPH2-deficient mice are susceptible to AF.19 To 
prevent the early atrial ectopy that initiates pAF, additional research is still needed into the 
mechanisms promoting atrial arrhythmogenesis, both in patient samples and in relevant 
animal models. As previously recognized, creation of large animal models that develop 
spontaneous atrial ectopy and pAF would facilitate evaluation of the mechanisms and 
sources of atrial ectopy that underlie the early stages of atrial arrhythmogenesis.1,16
Key knowledge gaps
1. What calcium handling (and other) mechanisms underlie ectopic PV activity in 
pAF patients?
2. Why does ectopy initiating from the PVs or other structures (vein of Marshall, 
coronary sinus, superior vena cava, etc) predominantly result in AF only in older 
individuals?
3. Are the mechanisms that underlie PV ectopy the same as those originating from 
other atrial regions?
4. Can targeted treatment of patients with frequent atrial ectopy safely and effectively 
prevent development of AF?
Pharmacotherapy for AF prevention/treatment
Drugs currently approved for AF management typically either block sodium channels to 
reduce excitability or block potassium channels to prolong repolarization. These drugs have 
limited efficacy and potentially serious side effects, most notably ventricular proarrhythmia. 
Some less specific drugs (amiodarone, dronedarone, ranolazine, etc) affect multiple channels 
and pathways, and are less proarrhythmic than agents that act on a single ion channel. An 
alternative strategy to ion channel blockade is to identify potential “upstream” targets. A 
recent comprehensive review of AF mechanisms and candidate drug targets details these 
possibilities.20 Here we briefly consider several newer AF drug targets in relation to the 
phases of AF development.
Atrial sodium and calcium handling—Ranolazine is currently approved by the US 
Food and Drug Administration (FDA) for treatment of chronic angina. It somewhat 
selectively suppresses late INa and has been shown to protect against postoperative AF in 
coronary artery bypass patients,21 a setting in which AF is promoted by elevated 
catecholamines and oxidant stress. In addition to CaMKII effects on RyR2, CaMKII 
hyperactivation also augments late INa.22 Ranolazine-mediated block of late INa may be 
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antiarrhythmic in part by attenuating CaMKII activation, as a consequence of improved 
export of intracellular Ca2+ by the Na+/Ca2+ exchanger. Ranolazine may also attenuate 
mitochondrial oxidant production.23
CaMKII, pathologically activated by oxidative stress,24 can phosphorylate many voltage-
gated ion channels in the heart, can stimulate inflammatory signaling by bolstering nuclear 
factor for κB (NF-κB),25 and can promote tissue remodeling and fibrosis by promoting 
myocyte cell death and expression of matrix metalloproteinase-9 (MMP9).26 CaMKII 
inhibition and late INa suppression strategies both are appealing because they are 
antiarrhythmic for ventricular as well as atrial arrhythmias, reducing concern about 
proarrhythmia. No CaMKII inhibitory agents are clinically available yet, but several are in 
development for cardiovascular indications including AF and likely will be available in 3–5 
years for proof-of-concept AF prevention studies.
Atrial oxidant stress/redox status—Because oxidant stress is upstream of late INa, 
CaMKII activation, and fibroblast and matrix metalloproteinase (MMP) activation, efforts to 
target oxidant generating sources in the atria seem logical. There is evidence for increased 
NADPH oxidase-2 (NOX2) activity in AF.27 NOX2 can be directly activated by myocyte 
stretch, and NOX2 activity modulates intracellular Ca2+ release.28 Other oxidant generating 
systems (NOX4, xanthine oxidase, myeloperoxidase) may also be important, with different 
oxidant generating systems likely relevant for patients with distinct subtypes of AF.
Flecainide29 and carvedilol30 have antiarrhythmic activities that result in part from redox 
modulation of RyR2; further mechanistic study of these drugs in secondary prevention of 
AF may be warranted. JTV-519, another RyR2 modulating drug, reduced Ca2+ leak and 
showed efficacy against AF but was withdrawn from clinical development due to ventricular 
proarrhythmia. JTV-519 derivatives are in clinical trials for HF and may prove useful in 
AF.31
Conduction velocity/heterogeneity—AF maintenance is facilitated by electrical/tissue 
remodeling that supports functional and structural reentry. As electrical reentry is favored by 
conditions that slow conduction or accelerate action potential repolarization, antiarrhythmic 
strategies may seek to repair slowed conduction and/or delay action potential repolarization. 
Experimental atrial gene therapy with connexin40 or connexin43 has been demonstrated to 
preserve conduction velocity and prevent AF initiation.32 Drugs in development target 
defective conduction velocity either by enhancing gap junction conductance (rotigaptide and 
others) or by attenuating atrial fibrosis (pirfenidone and others).20
Atrial-specific ion channels—Several ion channels are expressed more abundantly in 
atrial than ventricular myocardium. Therefore, these atrial-“specific” channels represent 
possible drug targets with little risk of ventricular proarrhythmia.33 Intracellular Ca2+ levels 
preferentially modulate atrial (vs ventricular) repolarization due to chamber specific 
differences in expression of Ca2+-activated potassium channel subunits (especially KCNN2 
and KCNN3).34 Genome-wide studies have associated KCNN3 variants with AF risk.35 
Expression of these channels is altered in experimental AF models,36,37 and agents that 
selectively suppress KCNN channel activity have been shown to exhibit antiarrhythmic 
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activity.37 These channels may also have important roles in other cell types (neurons, 
fibroblasts, vascular smooth muscle) that could affect AF risk.
Atrial structural remodeling/fibrosis
The atria are hemodynamically responsive endocrine organs. Under increased pressure, the 
atria release peptide hormones (atrial natriuretic peptide [ANP], BNP, endothelin-1 [ET-1], 
angiotensin-II [A-II], etc) that facilitate blood pressure (BP) and blood volume regulation.38 
These stretch-modulated hormones have autocrine, paracrine, and circulating activities, 
affecting the heart, lungs, blood vessels, and kidneys. The atria respond to acutely increased 
pressure by releasing natriuretic peptides (NPs) from myocytes that promote renal sodium 
excretion to lower systemic BP and volume. NPs also modulate systemic and coronary 
vascular tone and the electrical activity of cardiac myocytes via NP receptor-mediated 
activation of guanylate cyclase (GC). GC produces cGMP, which counteracts the effects of 
cAMP formed in response to sympathetic nerve activity (via beta-adrenergic receptor 
activation).
Changes in atrial structure, contractility, and electrical activity resulting from AF or 
underlying hemodynamic stress are due in part to the local impact of A-II, ET-1, ANP, and 
BNP release on atrial myocytes and fibroblasts. In the face of persistently elevated diastolic 
pressure (from hypertension, valvular dysfunction, HF, lung disease, and/or AF), the atria 
hypertrophy and develop interstitial fibrosis as a result of activation of the renin–
angiotensin–aldosterone system (RAAS), ET-1, and transforming growth factor-β (TGF-β) 
signaling pathways.39 Atrial fibrosis is also promoted by the activity of the transient receptor 
potential cation channel, subfamily M, member 7 (TRPM7), TRPC3, and by loss of the 
antifibrotic micro RNA-29 (miR-29).16 Atrial interstitial fibrosis promotes slowed and 
heterogeneous conduction.40 Fibrosis represents a response to injury, in the atria as well as 
in the lung, kidney, liver, and other organs.
Candidate antifibrotic therapies with the potential to slow or prevent the transition from 
paroxysmal to persistent AF include small molecule TGF-β antagonists, selective TRPM7 or 
TRPC3 antagonists, and miR-29 mimetics.16 In experimental hypertension and HF studies, 
pretreatment with agents that suppress TGF-β signaling or the RAAS (pirfenidone, 
spironolactone, omega-3 fatty acids, angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers [ACEi/ARBs]) have prevented or attenuated development of atrial 
fibrosis. Although effective when given before persistent hemodynamic stress,41 preclinical 
and clinical trial evidence so far has failed to demonstrate an antiarrhythmic benefit of these 
drugs in the treatment of AF in the presence of established HF.
Proteostasis and the microtubule network in AF—Aging is a powerful but 
nonmodifiable risk factor for AF. The proteostasis network is involved in the degradation of 
“old” proteins, the synthesis of new proteins within the endoplasmic reticulum (ER), and 
folding and trafficking of native proteins. Age-related conditions associated with abnormal 
proteostasis include Alzheimer, Parkinson, and Huntington diseases.42 Like these 
conditions, AF is also a strongly age-related disease associated with defective proteostatic 
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control.43 Figure 1 provides an overview of the primary proteostasis pathways, related 
signaling pathways, and significant modifiers of proteostasis.44
In several experimental AF models, normalization of proteostasis by overexpressing heat 
shock proteins (HSPs) attenuates structural remodeling and AF progression.45 HSPB1 binds 
to myofibrils and protects them from degradation in experimental systems and in human 
AF.45 HSPB1 also prevents structural remodeling by attenuating the conversion of G-actin 
to F-actin stress fibers and consequently protects against contractile dysfunction. Although 
the HSP response is transiently activated in patients with short episodes of AF, it becomes 
exhausted when AF persists. Atrial myocytes then lose their defense against structural 
changes, leading to AF progression.45 Atrial HSP expression may be a novel target for AF 
treatment.46 Geranyl-geranylacetone (GGA), originally used as an antiulcer agent, induces 
HSP synthesis in tissues, including the myocardium, through the activation of heat shock 
transcription factor-1 (HSF-1).46 Because GGA has protective effects on tachypacing-
induced structural remodeling in several experimental models, HSP induction by GGA may 
help to treat or prevent clinical AF.46 It will also be important to determine if HSP-inducing 
drugs such as GGA are effective in preventing AF progression in patients.
A novel role for histone deacetylase-6 (HDAC6) has been reported in the maintenance of 
atrial myocyte proteostasis.43 Analysis of atrial tissues from patients with permanent AF, 
tachypaced atrial myocytes, and other experimental model systems, revealed HDAC6-
induced tubulin deacetylation, degradation of α-tubulin networks, and contractile 
dysfunction. These processes were prevented by the HDAC6 inhibitor tubastatin A.43 Taxol, 
a microtubule stabilizer, has been shown to suppress Reactive oxygen species (ROS) 
production and AF in an in vitro model system.47 It is intriguing to note that colchicine, 
which depolymerizes tubulin, has been reported to reduce the incidence of both 
perioperative AF and AF recurrence after ablation. Tempering these findings, the recently 
reported COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative 
Atrial Fibrillation (COPPS-2) trial48 failed to meet its primary end-point of a reduction in 
postoperative AF based on an intent-to-treat analysis. However, this may have been due to 
treatment-induced gastrointestinal side effects, as a prespecified analysis of those on 
treatment found colchicine to be effective.49,50
Key knowledge gaps
1. What is the appropriate role for atrial selective ion channel modulators, 
antioxidants, and/or redox active agents in the treatment/prevention of AF?
2. Do profibrotic factors produced in other organs impact the atria? Does the opposite 
interaction occur?
3. How late can fibrosis-related atrial conduction abnormalities be reversed? 
Moreover, can these changes be reversed if the underlying hemodynamic 
abnormalities have been treated (by controlling BP, repairing valve function, 
treating HF, etc)?
4. Can modulators of the proteostasis or microtubule networks protect atrial function 
and/or reverse atrial dysfunction?
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Genetic/genomic insights into the mechanisms of human AF
Progress in characterizing the genetic loci associated with AF risk has been recently 
reviewed.51 In 2007, the first genome-wide association study (GWAS) of AF identified a 
single locus on chromosome 4q25 near the PITX2 gene that was strongly associated with 
AF. More recent studies have increased resolution by increasing the number of genotyped 
patients through the creation of global consortia. In addition to the 4q25 region, 8 additional 
AF-associated loci have been identified. The top genetic variants at these AF susceptibility 
loci are associated with a 5-fold gradient in AF risk.51 Identified genetic loci implicate 
candidate genes that encode transcription factors related to cardiopulmonary development, 
cardiac-expressed ion channels, and cytoskeletal/nuclear envelope proteins.51 Much work is 
ongoing in this area, and many additional studies are still required to identify causal genetic 
variants, the mechanisms linking the variants to AF risk, and the cellular signaling pathways 
that mediate the risk of AF associated with the genetic variants. These studies are likely to 
provide fundamental insights into the mechanisms that underlie atrial ectopy and the 
transcriptional changes that occur with electrical/structural remodeling that increases risk of 
AF. Genetic analyses may also improve AF/stroke risk stratification and, in the future, help 
to guide patient-specific treatment.
Key knowledge gaps
1. By what mechanisms do genetic variants associated with AF promote atrial ectopy 
and/or substrate changes?
2. Can genetic markers predict response to therapy, including preventive therapies?
3. Can genetic data enhance prediction of AF and be successfully incorporated into 
risk prediction tools?
AF risk prediction
AF risk factors include, but are not limited to, hypertension, obesity, HF, coronary 
atherosclerosis (CAD), valvular heart disease, thyroid disease, excessive alcohol intake, and 
family history of AF.52 Recently published risk prediction instruments have been derived in 
individuals of European and African ancestry and validated in 2 separate European 
cohorts.53,54 The risk scores include age, race, height, weight, systolic and diastolic BP, 
current smoking, use of antihypertensive medication, diabetes, and history of myocardial 
infarction and HF, and have acceptable discrimination and calibration.55 Additional putative 
AF risk factors include anatomic and physiologic assessments of structural heart disease, 
biomarkers,56 and genetic markers.57 For clinical utility, a novel marker must improve risk 
reclassification. Thus, although the inflammatory marker C-reactive protein is associated 
with incident AF, it does not significantly enhance risk prediction.58 However, NPs do 
improve risk prediction.59 Similarly, a recent report suggested that single nucleotide 
polymorphisms can enhance AF risk prediction and reclassification.57 Characteristics of 
optimal risk markers have been established.60 Novel elements considered in future AF risk 
prediction models require rigorous testing to ensure that they substantively improve risk 
prediction, have adequate calibration, and enhance risk reclassification in both discovery and 
replication cohorts. Development of accurate risk prediction tools is an important first step 
in the effort to prevent AF.
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Key knowledge gaps
1. Can existing risk prediction tools be improved and validated in prospective studies 
to yield a simple, yet highly predictive model for risk of incident AF?
2. Does incorporation of additional clinical characteristics, physiologic measures, and 
genomic factors improve risk prediction in a useful and usable manner?
3. Can prospective use of risk prediction tools enhance AF prevention or better direct 
AF treatment to limit progression to persistent AF?
Advancing AF prevention efforts by focusing on risk modification
Early identification and treatment of modifiable risks factors is a critical step toward primary 
prevention of AF. Estimates suggest that ∼57% of AF can be attributed to hypertension and 
other modifiable risk factors.61 Although there are additional modifiable AF risk factors, 
here we focus on hypertension, obesity/diabetes, HF, and sleep apnea as prevalent and 
important targets for primary prevention of AF. The relationships among these risk factors 
are outlined in Figure 2.
Secondary prevention of AF recurrence should similarly include efforts to optimize weight, 
control BP, and diagnose and treat sleep apnea. Controlled interventions compared to usual 
care are instructive, and risk reduction programs following AF ablation could become 
standard medical management practice. Creation and evaluation of “post-AF ablation rehab” 
programs in which patients are followed for several months after ablation and intensively 
counseled on BP control, dietary issues, and sleep apnea recognition and treatment should be 
a priority. Although these factors have been independently associated with risk of AF 
recurrence, the impact of their treatment on AF incidence and burden has not yet been 
collectively or systematically addressed. Such efforts are strongly encouraged.
Hypertension
Hypertension promotes left ventricular (LV) dysfunction, LA dilation, and cardiac fibrosis. 
A recent study demonstrated that hypertension promotes heterogeneous conduction and 
repolarization. Additionally, hypertension promotes dilation of the PVs and abbreviation of 
PV tissue refractoriness,62 especially in patients with pAF. Effective treatment of 
hypertension has been associated with a reduction in LV mass and decreased incidence of 
new-onset AF.63 Early and effective BP control is a logical early target for primary 
prevention of AF; however, there are several challenges. These challenges for primary 
prevention include (1) identification of whom to treat and when to begin, (2) a lack of 
consensus about the most effective treatments, (3) a lack of provider adherence to guidelines 
for hypertension therapy, (4) an inability to monitor BP in “real time,” and (5) an inability to 
identify asymptomatic hypertensive individuals prior to the onset of AF.
Aggressive screening using clinical risk prediction tools can help to identify those who 
would benefit the most from treatment to prevent complications of hypertension, including 
atrial remodeling. Home BP monitoring to evaluate the efficacy of treatment is under 
investigation.64 Although AF is not being evaluated as an end-point, drug compliance and 
efficacy studies will yield important data. Development of easier to use, more “real time” or 
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even continuous ambulatory BP monitoring devices would constitute a significant advance 
that would enhance identification and improve management of hypertension.
Which antihypertensive approaches are best for preventing AF?: A-II promotes 
sympathetic nervous system activity, systemic oxidant production, systemic and atrial 
inflammation, development of atrial fibrosis, gap junction uncoupling, impaired atrial Ca2+ 
handling, and ion channel remodeling.65 Although studies of RAAS inhibition have been 
disappointing for the prevention of recurrent AF, metaanalyses of patients with LV 
hypertrophy or LV dysfunction suggest that use of ACEI/ARBs can prevent 20%–30% of 
new-onset AF events.66 ARBs may be superior to β-adrenergic receptor blocker therapy for 
primary AF prevention. In the Losartan Intervention For Endpoint reduction in hypertension 
study (LIFE) randomized trial, new-onset AF was significantly reduced by use of losartan vs 
atenolol in patients with LV hypertrophy.67 Similarly, in hypertensive patients without 
structural heart disease, ACEI/ARBs were more effective in preventing AF than β-blockers 
and diuretics.68 ARBs may be useful adjuncts to amiodarone in preventing AF recurrence 
following DC cardioversion in patients with persistent AF.69 However, as monotherapy, the 
impact of RAAS blockade on secondary AF prevention has been mixed, perhaps related to 
the timing of ACE/ARB therapeutic initiation70,71 and the antecedent presence of 
hypertension. Relative to A-II, less attention has focused on the role of aldosterone in AF. 
Upstream of A-II, aldosterone also promotes atrial oxidative stress, inflammation, fibrosis, 
and structural/electrical remodeling. In the setting of hypertension and/or HF, aldosterone 
antagonists warrant greater evaluation as a strategy to prevent AF or limit its progression.72 
Assessment of AF incidence and burden as secondary outcomes in prospective studies of 
novel antihypertensive drugs is still strongly encouraged.1
What is the role for renal sympathetic denervation?: Pharmacologic control of BP is 
limited by patient compliance, underrecognition of adequate control, and the presence of 
drug-resistant hypertension.73 Renal sympathetic denervation (RSD) has been suggested as a 
strategy to simultaneously address both compliance and drug-resistance issues, but a recent 
well-designed and conducted study (Symplicity-3) failed to demonstrate a benefit of RSD 
when compared to a sham-procedure, medically treated control group.74 The results of the 
Symplicity-3 study are limited by the failure to assess whether the renal nerves were 
effectively denervated. A meta-analysis of small studies in which the impact of concomitant 
RSD in AF patients undergoing pulmonary vein isolation (PVI) suggests a potential benefit 
of the procedure in patients with resistant hypertension.75 The future of RSD as a primary 
antihypertensive or anti-AF therapy is currently uncertain, in part due to the lack of a clearly 
defined acute end-point of RSD. Appropriately powered randomized controlled trials 
(RCTs) with sham controls are needed to clarify the value of this approach.
Key knowledge gaps
1. What is the optimal approach for monitoring BP in patients at risk for AF?
2. Which antihypertensive treatment is best for preventing AF?
3. What, if any, is the role of RSD in the prevention of AF in hypertensive patients?
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Obesity/diabetes
Obesity impacts many aspects of health, including AF risk. Obese individuals are ∼ 2.5-fold 
more likely to develop AF than nonobese individuals,76 and increased body mass index 
(BMI) is associated with increased risk for postoperative AF after cardiac surgery.77 Obesity 
is incorporated in the Framingham AF risk assessment tool,54 and AF risk is greatest for 
individuals with central obesity. Interestingly, elevated weight and HbA1c levels are 
associated with greater risk of developing persistent (rather than paroxysmal) AF.78
Experimental studies provide insight into how obesity promotes AF. In a sheep overfeeding 
model, increasing weight was associated with increased mean arterial pressure and LA 
pressure,79 leading to progressive increases in LA and right atrial volumes. Conduction 
slowing, heterogeneity, and delayed activation were also apparent. Rate-dependent 
conduction slowing was greater in obese than in overweight or control animals. Moreover, 
increased weight was associated with increasing frequency of spontaneous AF episodes, and 
the number and duration of inducible AF episodes. Increased weight has also been 
associated with inflammation, increased concentrations of profibrotic signaling molecules, 
and the development of atrial fibrosis.79 Taken together, these data suggest that obesity 
increases AF susceptibility and burden.
From the perspective of prevention, it is critical to determine whether weight loss is 
sufficient to decrease AF risk or burden. A recent study assessed the impact of weight loss 
on AF burden and severity in 150 overweight/obese patients with symptomatic AF.80 
Patients were randomized to either an intensive weight loss intervention or a general 
lifestyle (control) group. Lipids, glucose, and BP were carefully monitored and managed in 
both groups. At 12-month follow-up, BMI and waist circumference decreased more in the 
intervention than in the control group, as did AF symptom burden and severity.80 Efforts to 
replicate and extend this study to other populations are warranted.
In addition to obesity, hypoglycemia in individuals with type 2 diabetes mellitus (T2DM) 
can provoke ectopy, bradycardia, and AF.81 In an observational study of 25 insulin-
dependent T2DM individuals with at least 2 other cardiovascular risk factors for AF 
(hypertension, dyslipideia, smoking, obesity), blood glucose and cardiac electrical activity 
were continuously monitored for 5 days. Atrial ectopy was 4-fold higher and bradycardia 8-
fold higher during nocturnal hypoglycemia than during euglycemia, but neither was 
different during the daytime.81 Autonomic and metabolic factors are highly interrelated, and 
both contribute to AF risk.
Given the global rise in the prevalence of obesity and diabetes, aggressive efforts are needed 
to promote healthy eating, regular physical activity,5 and weight control while monitoring/
managing diabetes, lipid levels, and hypertension. These efforts may significantly reduce AF 
risk. Likewise, in secondary prevention, similar efforts may reduce AF symptom burden, 
and episode frequency and duration. Future research should also assess the burden of 
asymptomatic AF in relation to modification of risk factors. Success in these goals would 
likely also reduce the risk of stroke and HF. These efforts will require the collective 
education and collaborative efforts of heart rhythm professionals, cardiologists, general 
practitioners, nurses, educators, and the public.
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Key knowledge gaps
1. Can reversal of cardiometabolic risk factors reduce the incidence of AF in patients 
with AF (ie, secondary prevention) or prevent AF altogether (primary prevention)?
2. What is the relationship of age to the reversibility of cardiometabolic risk factors?
3. Does weight loss reverse the fibrotic/hypertrophic atrial remodeling observed in 
obesity? Does the nature of the diet (or intervention) under which weight is lost 
affect the durability of weight loss or atrial remodeling?
4. What molecular pathways underlie obesity related atrial remodeling?
5. What are the most effective/efficient ways to achieve durable weight loss?
6. What mechanisms link nocturnal glucose regulation with autonomic activity and 
atrial ectopy?
Heart failure
Like AF, HF is a burgeoning epidemic, affecting more than 5 million individuals in the 
United States. HF patients have an increased risk of developing AF, due to both underlying 
cardiovascular disease and the remodeling and hemodynamic impairment associated with 
HF syndromes. The prevalence of AF in those with HF ranges from 4% to 40% as the 
degree of symptomatic impairment increases and thus is 4- to 40-fold greater than the 
background population rate.82 Patients with either systolic or diastolic dysfunction are at 
increased risk of AF. Although AF is common in HF patients, fewer antiarrhythmic drugs 
(AADs) are safe in HF patients compared to those without structural heart disease.83 Only 2 
antiarrhythmic drugs AADs are guideline-recommended in HF patients (amiodarone and 
dofetilide), and both have limiting adverse effects. Amiodarone leads to end-organ 
toxicities, and dofetilide has significant proarrhythmic risk. Catheter ablation is a promising 
therapy in patients with AF and concomitant HF, but recurrence rates may be higher. Thus, 
as with most cardiovascular disorders, the most effective treatment strategy for patients with 
AF and HF would be prevention.
Some components of optimal medical therapy for HF may reduce the risk of new-onset AF. 
Aldosterone antagonists, including aldosterone and eplerenone, may prevent AF in HF 
patients.84,85 Additionally, in HF patients who are β1-adrenergic receptor 389 Arg 
homozygotes, bucindolol may prevent new-onset AF.86 The Genetically Targeted Therapy 
for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure 
(GENETIC-AF) trial is being conducted to evaluate the efficacy of genotype directed 
bucindolol (NCT 01970501). It seems logical that effective HF treatment may lower the 
incidence of new-onset AF. Thus, emerging HF therapies may have an important role in the 
prevention of AF, and the incidence of AF should be included as an outcome measure in 
current and planned HF clinical trials.
Key knowledge gaps
1. Does aldosterone inhibition prevent new-onset AF in patients with HF?
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2. Can genotype-directed therapy be used to guide prevention of AF in patients with 
HF?
3. Can emerging pharmacotherapies for HF reduce the risk of AF?
4. What is the best method of secondary prevention for AF in patients with HF? What 
is the best catheter ablation strategy in patients with HF?
Sleep disordered breathing
Sleep disordered breathing (SDB) afflicts more than 15% of adults and 30%–50% of 
cardiovascular disease (CVD) patients. SDB causes intermittent hypoxia, intrathoracic 
pressure swings, and altered preload and afterload. Autonomic imbalance during SDB 
occurs via increased vagal activity during apnea/hypopnea (AH) episodes and hypercarbia/
hypoxia-induced sympathetic nervous system activation after AH episodes.
Epidemiologic studies document a strong association of SDB with AF (odds ratio 2–4), even 
after accounting for obvious confounding factors (age, BMI, hypertension, self-reported 
HF).87 Different mechanisms underlie central sleep apnea (CSA) vs obstructive sleep apnea 
(OSA). Among the elderly, stronger associations have been reported between AF and CSA 
compared to OSA. Moderate to severe SDB (AH index ≥24) conferred the greatest risk of 
AF.87 Male gender, hypertension, and diabetes are apparent risks for AF in SDB, and, based 
on cardiac magnetic resonance imaging (MRI), SDB is associated with greater right 
ventricular volume and LV mass and larger LA dimensions.88
Figure 3 summarizes some of the downstream consequences of SDB that likely contribute to 
AF risk. Although continuous positive airway pressure (CPAP) reduces AF recurrence after 
ablation and cardioversion in those with SDB, existing data are limited by retrospective 
design and intrinsic biases of potential nonadherence with other aspects of medical care in 
those declining CPAP treatment.89–91 A logical primary AF prevention RCT would assess 
the impact of SDB treatment on AF outcomes. Future research into SDB and AF should 
collect objective cardiac function data as well as measurement of autonomic function and 
markers of systemic inflammation and oxidative stress. Holter recording of both daytime 
and nocturnal ECGs would help to clarify SDB pathophysiology.
Large, adequately powered, prospective longitudinal studies are needed to rigorously 
identify the class and severity of SDB and assess the temporal relationships of SDB and its 
determinants to incident AF development. These studies would facilitate characterization of 
subgroup susceptibilities to SDB and AF in terms of age, sex, race, underlying cardiac 
disease, and genetic variation. This would facilitate early identification of vulnerable groups 
that could be intensively targeted for AF screening and prevention.
Key knowledge gaps
1. What is the impact of SDB as a relevant exposure in ongoing and planned AF 
clinical research?
2. In planned RCTs, what is the impact of SDB treatment on AF outcomes?
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3. What is the additive predictive value of SDB indices to AF/stroke risk prediction 
algorithms?
Prevention of AF recurrence, progression, and sequelae
In the cases where AF is established, better treatments that prevent AF recurrence or reduce 
its burden may decrease the incidence of stroke and/or the development of 
cardiomyopathy/HF. Given the poor efficacy of antiarrhythmic drug therapy and limited 
efficacy of catheter ablation in persistent forms of AF, early interventions that terminate AF 
or prevent the progression of AF may have significant clinical benefit. Research in several 
areas is needed to advance these goals.
Imaging
Functional imaging of the atria—Electroanatomic mapping and imaging of the atria 
have evolved from preclinical use of electrode arrays and optical imaging. This evolution 
has led to the routine clinical use of percutaneously deployed arrays that record unipolar and 
bipolar electrograms and propagation characteristics from their temporospatial distribution 
on the millimeter scale. Optical mapping uses voltage- or Ca2+-sensitive dyes to derive 
action potential and propagation characteristics on the submillimeter to millimeter scale. 
These tools continue to produce new insights and functional information.92 ECG-based 
imaging is currently leading the way in clinical application of noninvasive activation 
mapping, but other technologies are also under development.
Myocardial scar and fibrosis are important barriers that disrupt wavefront propagation, 
create anisotropy, and promote reentry. Noninvasive imaging of scarred atrial myocardium 
demonstrates various correlations with overall scar burden, including both duration of AF 
and outcomes following catheter ablation.93 Imaging of atrial scar/fibrosis may enhance risk 
stratification and patient selection for AF ablation. Using late gadolinium enhanced cardiac 
magnetic resonance imaging (LGE-CMR) to detect scar, the DECAAF study has confirmed 
the relationship between delayed myocardial enhancement and risk of recurrence of AF after 
ablation.94 However, LGE-CMR operates at the limits of resolution dictated by the 
biophysics of MRI and operator expertise, and objective and automated measurement of 
enhancement and the ability to correlate point-by-point enhancement with local 
electrophysiologic characteristics95 have not been adequately developed to the point that 
LGE-CMR can be reliably used to identify arrhythmogenic sources or targets for site-
specific treatment delivery. Additionally, MRI has been used to define ablated tissue in 
patients who have undergone ablation; however, there are challenges in differentiation of 
scar from atrial fibrosis vs scar from ablation. As MRI and other techniques emerge and 
mature, electroanatomic mapping will remain an important part of validation of new 
imaging techniques. Research developing more sensitive and reliable techniques to detect 
atrial scar/fibrosis is still needed.
Validation of methods for noninvasive imaging of AF—The 12-lead ECG has 
limited ability to identify AF mechanisms or to localize atrial arrhythmias. Development of 
electroanatomic mapping systems has transformed AF treatment and provided tools to help 
understand the mechanisms of atrial arrhythmogenesis. Refinement of both the mapping 
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tools and the mechanistic insights into AF are pointing toward the importance of wide area 
(panoramic) contact mapping of fibrillatory wavefronts.96 While focal mapping strategies 
focus on the scatter of localized electrograms, wavelets and voltages, 97 wavefronts that are 
critical to the arrhythmia identified by contact mapping96 may theoretically involve 
sufficient cardiac mass to be resolved from the body surface92 using similar concepts and 
approaches to the “inverse solution” currently used in noncontact endocardial mapping.98 
This provides motivation for further refinement of noninvasive electrocardiographic 
activation mapping from the body surface.92
There are now early reports of the clinical use of electrocardiographic mapping (ECM),99 a 
3D surface ECG-based noninvasive epicardial mapping system that provides simultaneous 
global chamber mapping derived from a 252-electrode vest applied to the patient's torso. 
The precise electrode positions and juxtaposition with the heart are derived from a 
noncontrast thoracic CT scan that provides high-resolution images of the heart and the vest 
electrodes in situ. ECM has been used to noninvasively reconstruct nonfibrillatory atrial 
arrhythmias, with a high diagnostic accuracy100 in a small series of patients with AF. ECM 
provides only epicardial mapping, precluding direct mapping of the endocardium or the 
septum. AF and AT with a low signal-to-noise ratio on the torso pose analytic challenges, 
particularly during high ventricular rates or in the absence of reliable QRST-subtraction 
algorithms.99 The impact of ECM on procedure times, fluoroscopic exposure, and the 
efficacy of ablation of atrial arrhythmias seems promising but requires systematic 
assessment.
Key knowledge gaps and research needs
1. Develop better, reliable, and reproducible techniques for imaging atrial scar and 
fibrosis.
2. Validate body surface mapping and determine its utility in guiding treatment of AF.
3. Improve technologies associated with panoramic AF wavefront imaging, 
particularly in patients with advanced forms of AF.
Nonpharmacologic treatment of AF
AF mapping/ablation—Mapping and ablation are important tools and therapies for 
secondary AF prevention, but current strategies still yield suboptimal results that result in 
frequent early and late AF recurrence. In recent multicenter trials, 1-year ablation success 
rates were 50% to 70% (single to multiple procedures) in pAF,82 with much lower success 
rates in patients with persistent AF or with comorbidities such as untreated SDB and/or 
hypertension. Important knowledge gaps include how to prevent AF recurrence in more 
patients early (first year) after ablation82 and over the longer term, because AF can recur late 
(eg, several years or more) following ablation. Better tools and techniques are needed to 
achieve durable PVI,82 including an enhanced understanding of AF mechanisms and more 
patient-specific identification of ablation targets. Identification of the factors that contribute 
to the development and progression of AF at the individual level will be critical for success. 
Cohort studies that incorporate biomarkers, genomics, and electroanatomic imaging with 
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clinical parameters may guide development of more personalized approaches to ablation 
technique and improve subsequent outcomes.101
Achieving durable PVI remains technically challenging.82 Cardiac MRI (cMRI) studies 
show that nontransmural lesions can cause inflammation that initially appears to acutely 
result in PVI but permit recurrent conduction once the edema subsides.102 Gaps as small as 
1.5 mm may permit electrical reconnection between the LA and PVs.103 Future studies 
should evaluate whether real-time cMRI, other imaging modalities, or pharmacologic 
challenge104 can distinguish permanent from functional block, to indicate when additional 
ablation is required at the initial procedure. Two ongoing trials (NCT01490814, 
NCT01824394) are testing the hypothesis that tissue ablation can be enhanced by using 
cryoballoon ablation rather than standard radio-frequency ablation. Additional trials 
(NCT01693120, NCT01824394) are evaluating the use of circular ablation catheters and 
different mechanisms of current delivery to improve radiofrequency ablation and PVI. 
Development of alternate energy sources (eg, LASER), catheters that provide direct 
visualization of ablated tissues, and use of real-time contact-force sensing to ensure 
consistent lesion delivery may also improve procedural efficacy.
There is a need to identify individualized mechanism-based ablation targets. Future studies 
should include mapping of non-PV triggers, which can emerge after PVI to cause AF 
recurrence and may be challenging to map.105 It is unclear which techniques can be used to 
identify infrequent ectopic triggers and what end-points should be used for their ablation. 
Recent approaches to empirically ablate “typical” trigger sites106 should be compared 
against patient-specific mapped non-PV triggers.105
AF substrate ablation may prevent AF recurrence if PVs reconnect or non-PV triggers 
emerge.82 Substrate targeting may be central for effective treatment of persistent AF and 
increasingly important in pAF cases in which structural remodeling and fibrosis, electrical 
remodeling, and conduction slowing107 are significant. Defining substrate has been difficult, 
and the results with adjunctive ablation in clinical trials have been mixed. Although AF is a 
disorganized rhythm, several studies now conclude that this disorganization may result from 
organized sources (rotors or focal sources),96 as originally demonstrated in animal 
models.108 Early results from clinical studies suggest that ablation of focal sources improves 
out-comes.96 This contrasts with the alternative viewpoint that complex activity per se may 
cause AF without underlying drivers.109 Efforts to resolve the mechanistic origin and 
significance of rotors in AF are warranted.
Autonomic activity is mediated by discrete ganglionated plexi (GP) on the atrial 
epicardium.110 It alters global spatial gradients of repolarization and may influence localized 
or nonlocalized mechanisms. Intrinsic cardiac autonomic nerve activity precedes the onset 
of AF in ambulatory dogs,111 and it has been suggested that ablation of GP with surgical or 
catheter-based techniques might be effective in controlling AF. A recent RCT suggests that 
GP ablation may be a useful adjunct to PVI.112 Efforts to replicate this observation are 
warranted, with careful short- and long-term ECG monitoring of procedural efficacy and 
procedural side effects.
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New approaches to mapping and ablation may target regions of oscillating action potential 
duration (APD) that can cause wavebreaks leading to AF.113 Better approaches are needed 
to map atrial repolarization dispersion114 and to determine whether it is related to autonomic 
innervation.112 Conduction slowing is common in AF patients115; at rapid rates, this may 
initiate AF.115 Imaging studies (delayed enhancement MRI93 or other approaches) may help 
to assess the mechanisms underlying conduction slowing and guide the choice of 
pharmacologic interventions to slow/reverse the development of atrial fibrosis.
Key knowledge gaps
1. Can ablation of rotors or non-PV triggers improve long-term success rates after 
PVI?
2. Can imaging-guided substrate modification improve ablation outcomes in patients 
with persistent forms of AF?
3. Will alternative energy sources or contact force sensing improve PVI durability, 
long-term freedom from AF, and procedural safety?
4. Can therapies targeted at preserving atrial conduction velocity prevent AF?
5. Can more detailed understanding of AF mechanisms help target ablation and 
improve both the effectiveness and safety of AF ablation?
Device-based monitoring—Transcutaneous and implantable monitoring devices can 
screen for AF and categorize AF burden. It is increasingly likely that these devices will have 
a role in monitoring responses to pharmacologic and ablation therapies. Twice-daily, 
community-based handheld ECG monitoring was effective in detecting silent AF,116 and 
subclinical AF detected by pacemakers has been identified as a risk factor for stroke.117 
Given the burden of unrecognized or silent AF,118 it will be important to develop cost-
effective approaches to screen for atrial ectopy, subclinical AF, and clinical AF in the 
community. New devices capable of prolonged ECG recording (weeks to years) could 
facilitate natural history studies, diagnosis, prognosis, and assessment of response to 
therapy. These technologies may enable rigorous assessment of the predictive power of 
PACs on the development AF, assessing the interaction of PAC burden with 
electrocardiographic measures of autonomic status and P-wave morphology. They may also 
offer the ability to detect arrhythmia precursors to sustained AF in patients at increased risk 
of stroke117 and to resolve whether and when AF occurs in clusters.119 Monitoring could 
provide insights into whether/how cerebral embolic events are temporally related to AF. 
These important questions may be addressed with devices available now or in the very near 
future.
Another unresolved question is whether monitoring can empower or motivate patients to 
participate more actively in their own care. Evidence is accumulating with respect to the 
benefits of patient self-monitoring for a variety of chronic conditions, including obesity and 
BP. Patient self-monitoring of BP yields improved outcomes, at least in short-term follow-
up.120 This is relevant with respect to concerns about workforce gaps for cardiovascular care 
and the sustainability of integrating extensive self-monitoring or continuous physiologic 
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data into clinical workflows.121 Bluetooth ECG transmission to smartphones or other 
personal digital devices might serve as prompts to change medication or to seek medical 
attention if AF persists.122 Finally, prolonged monitoring may help to quantitatively assess 
and compare the efficacy of various therapies.
Device-based therapies
Atrial pacing: The effects of atrial pacing strategies on AF prevention have been 
systematically reviewed.123 Briefly, considerable efforts over the last 25 years to develop 
pacing therapies for preventing or treating AF have not identified effective pacing strategies. 
This conclusion is based on both observational and RCTs. In contrast, there is strong 
evidence that minimizing ventricular pacing at the expense of atrial pacing in patients with 
bradycardia prevents the appearance of symptomatic AF.124
Device-triggered therapy: While pacing approaches appear largely ineffective, devices are 
playing a growing and key role in detecting and treating AF and preventing cerebral 
thromboembolism. For example, the recent CRYSTAL AF trial demonstrated that implanted 
loop monitoring in patients with cryptogenic stroke results in improved detection of AF and 
subsequent anticoagulation.125 The role of monitoring devices for targeted use of rapidly 
acting oral anticoagulants (OACs) upon detection of intermittent AF is also being studied 
(NCT01706146).
Device-based autonomic modulation: Autonomic nerve activity is an important AF 
trigger; its role in the pathophysiology and treatment of AF has recently been reviewed.126 
Autonomic nerve activity may be a target for both direct and indirect therapeutic 
intervention/modulation.1 Devices that provide safe, effective, and targeted autonomic 
modulation that are easily controlled and do not cause nerve damage may represent a 
valuable therapeutic intervention. Parasympathetic activity, typically mediated by vagal 
nerves, can suppress sympathetic stimuli at pre- and postsynaptic levels.126 Baroreflex 
stimulation devices have been shown to prevent hypertension by suppressing sympathetic 
nerve activity.127 Direct cervical vagal nerve stimulation has been reported to attenuate 
development of HF in dogs, rats, and humans.126 At stimulus strengths that did not reduce 
heart rate, low-level vagal nerve stimulation suppressed AF induction in dogs subjected to 
intermittent rapid atrial pacing.126 Remodeling secondary to vagal nerve stimulation may 
attenuate sympathetic nerve activity and AF inducibility. Skin is well innervated by 
autonomic nerves. Recent small studies suggest that neuromodulation through skin or 
subcutaneous tissues may also help to control AF using either a transcutaneous approach128 
or acupuncture.129 Further studies are required to determine if these novel methods will be 
clinically useful.
Key knowledge gaps
1. Can device-based screening for AF improve stroke prevention and downstream 
clinical outcomes?
2. Can autonomic modulation meaningfully reduce AF recurrence or prevent AF in 
those at high risk?
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AF-related stroke prevention
Brain imaging
Given the impact of AF on stroke and the association of AF with cognitive dysfunction,130 
brain imaging may improve the care of AF patients. Brain imaging can help to stratify stroke 
risk in AF patients. Presence of subclinical brain infarcts is robustly associated with the 
subsequent risk of stroke. Short-term risk of stroke after transient ischemic attack (TIA) was 
3-fold higher in patients with a brain infarct on MRI compared to those without.131 As 
existing clinical stroke risk prediction scores are imperfect in delineating stroke risk,132 use 
of brain imaging may significantly improve stroke risk stratification in patients with AF.
Brain imaging may also assist in stratifying risk of intracerebral hemorrhage in patients 
being considered for anticoagulant therapy and serve as a surrogate marker of stroke that 
could improve the efficiency of clinical trials for prevention of thromboembolism in AF.133 
Surrogate end-points are not appropriate for all trials, but their selective use may facilitate 
exploratory trials that are currently impossible. This strategy may be helpful in AF.
In AF patients undergoing radiofrequency ablation procedures, many patients have evidence 
of asymptomatic cerebral emboli visible on postprocedural MRI brain scans.134 Lowering 
the peak energy delivered during the ablation procedure or intensifying anticoagulation may 
reduce the incidence of these emboli, at the cost of increased procedural time.134 Further 
study of brain imaging may help to evaluate the significance of these emboli and to reduce 
their incidence.
Pharmacologic advances in AF-related stroke prevention
Since 2009, 4 non–vitamin K-dependent oral anticoagulants (NOACs) that selectively 
inhibit either thrombin (dabiga-tran) or factor Xa (rivaroxaban, apixaban, edoxaban) have 
been evaluated for stroke prevention in AF.135 Compared to warfarin, NOACs offer relative 
efficacy, safety, and convenience. Warfarin efficacy and safety depend on the quality of 
anticoagulation control, as reflected by the average time in therapeutic range (TTR). Due to 
the difficulty of achieving therapeutic international normalized ratios (INRs) quickly after 
starting warfarin, an increased risk of stroke has been observed in the 30 days after initiation 
of warfarin.136 Given the availability of NOACs and the recognition that well-controlled 
anticoagulation with warfarin offers high efficacy and safety, there is an evolving clinical 
practice shift in which the risk threshold for treatment is being lowered. There is increasing 
focus on identifying patients at very low risk of stroke—those under 65 years old with AF in 
the absence of other risk factors, in whom OAC is not indicated.
For the patients who do require OAC therapy, questions remain. Undertreatment with 
warfarin is common, with 30%– 50% of “high-risk” AF patients not receiving 
anticoagulation.137 The causes for this practice need to be better understood through 
population-based studies and registries. Some investigators advocate a need to identify the 
newly diagnosed AF patients who are likely to do well on warfarin (with high TTR). A 
recent ESC position document recommends that use of the SAMeTT2R2 score138 be 
considered to help identify newly diagnosed, warfarin-naïve AF patients who would do less 
well on warfarin (poor TTR; if SAMeTT2R2 score > 2) and who would require additional 
Van Wagoner et al. Page 20
Heart Rhythm. Author manuscript; available in PMC 2015 May 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
interventions to achieve acceptable anticoagulation control, or be best initially treated with a 
NOAC instead of warfarin.139 This score seems predictive of labile INRs and consequently 
more thromboembolism, bleeding, and death.140
An unresolved issue requiring clinical evaluation is the lack of direct comparisons between 
the 4 NOACs for the AF population as a whole and/or for subpopulations at particularly 
high risk of stroke or bleeding. One such population is individuals with AF and impaired 
renal function, as all NOACs are at least partially excreted via the kidneys.135 Another is the 
group of patients with prosthetic valves.
Cryptogenic stroke/endothelial dysfunction/thromboembolic risk prediction
One-third of ischemic strokes are labeled “cryptogenic” because a definite cause cannot be 
established. Although clinically apparent AF is a well-established cause of cardioembolic 
stroke, clinically apparent AF is often preceded by subclinical AF, atrial ectopy, or other 
nonspecific atrial tachyarrhythmias.117 It is unknown when stroke risk begins during 
arrhythmia progression; evidence suggests that stroke can occur before the manifestation of 
clinically apparent AF. Even 6 minutes of subclinical AF has been associated with increased 
risk of subsequent ischemic stroke, in the absence of clinically apparent AF.117 Frequent 
atrial ectopy may correlate with increased stroke risk even among patients who have not yet 
developed AF.141 In cryptogenic stroke patients, ambulatory ECG monitoring to rule out 
subclinical AF often shows frequent atrial ectopy immediately after the stroke, progressing 
to AF within months.142 Many cryptogenic strokes likely result from subclinical AF not 
identified before stroke or during the stroke hospitalization. Observational studies using 
extended ambulatory ECG monitoring after stroke have found previously undiagnosed AF in 
many patients, up to 25% after several months of monitoring.142
LA occlusion devices
Devices to facilitate left atrial appendage (LAA) occlusion may become a safe, evidence-
based method to prevent stroke.143 The merits of intravascular vs intrapericardial devices 
have not yet been assessed. Progress in this field has been sparked by the composite surgical 
experience attesting to the efficacy of LAA exclusion in preventing cerebroembolic events. 
Other intravascular occlusion and intrapericardial external LAA ligation devices are also 
being developed and studied. Critical evaluation of the long-term efficacy of these devices is 
warranted.
Key knowledge gaps
1. Does population-based screening for AF decrease stroke and improve survival?
2. Is population-based AF screening cost-effective?
3. What is the best method for AF detection and diagnosis in cryptogenic stroke 
patients?
4. Is antiplatelet therapy or OAC the most appropriate medical therapy for patients 
with cryptogenic stroke?
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5. Can risk stratification scores, such as SAMeTT2R2, be used to help select OAC 
therapy and improve outcomes, including bleeding and stroke?
6. Does NOAC therapy improve outcomes in nonvalvular AF patients who are at low 
risk of stroke (eg, CHA2DS2-VASc=1)? What is the optimal treatment strategy in 
these patients?
7. Can LAA closure technologies serve as a safe and effective alternative to 
pharmacologic stroke prevention?
The need for innovative research structures and methods
Clinical trials in the era of financial constraints
It is estimated that less than 15% of major recommendations from clinical practice 
guidelines in cardiovascular medicine are grounded in high-quality evidence, including 
those for AF treatment.7 The evidence gap will continue to widen unless the productivity 
and efficiency of the clinical research enterprise are improved. The current clinical trials 
system is encumbered by regulatory and administrative burdens.144 Trial startup is 
hampered by poorly coordinated institutional review board (IRB) activities, lack of 
standardized data collection (with limited reusability of case report forms), and institution-
specific contract requirements. Trial monitoring often uses retrospective evaluation rather 
than building quality into study design.145 Systemic improvements are needed to provide 
patients (with or at risk for AF) with the evidence needed to optimize prevention, diagnosis, 
and treatment. Creation of AF-focused clinical research networks may improve AF trial 
design and increase likelihood of funding following competitive review. It is often possible 
to use a factorial design or a predefined substudy to address several questions within one 
trial.146 Some networks, such as the Canadian Heart Rhythm Society, provide a regular 
forum where investigators, particularly junior investigators, can propose study ideas and 
receive feedback from researchers and clinicians to help develop and implement their 
proposals. Networks can accelerate trial enrollment more than simply increase the number of 
sites.
In addition to a role for research networks, four key recent developments will enhance AF 
and related clinical research. First, electronic health records (EHRs) are becoming 
ubiquitous for basic data collection, as they are essentially mandatory in the United States 
due to federal meaningful use criteria.147 Data integration across EHRs will enable analysis 
of data in structured formats that facilitate analysis. Second, clinical registries are being used 
more effectively for clinical research. The potential for synergy between EHRs and 
registries is significant. Third, a “patient-centered” approach to data collection now 
complements the above-described EHR and registry networks. Both patient-reported 
outcomes and physiologic data captured directly from portable personal devices and 
wearable technologies are proliferating. Heart rhythm detection and monitoring devices are 
leading this effort and will impact AF research. In perhaps the most innovative approach, 
patients and their advocates are now being included in the research ecosystem. This is most 
visible in the Patient-Centered Outcomes Research Network (PCORnet).148 Not 
surprisingly, the greatest advocates for high-quality research are patients and their families.
Van Wagoner et al. Page 22
Heart Rhythm. Author manuscript; available in PMC 2015 May 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Patient involvement in AF prevention research
A recent insightful essay notes that “prevention needs to be connected to things people 
already value to make prevention a daily reality.”149 A central challenge in AF prevention 
and improving care is the translation of research findings to patient-centered clinical 
practice. The research priorities of clinical trials are not always concordant with patient 
priorities in preventing, treating, and living with AF. Patients are looking for clear guidance 
with respect to how best to reduce their risk and burden of AF. Emerging evidence related to 
diet,80 caffeine,150 yoga,151 and acupuncture129 represent potentially important steps 
forward in the incorporation of patient-driven prevention research. Social networking may 
have a significant role in the prevention and treatment of AF, similar to ongoing efforts in 
obesity and diabetes management.152
The patient perspective is important at both individual and population levels. Clinicians 
treating AF often consider patients' preferences individually, as reflected in clinical practice 
guidelines.153 Because AF is a complex and heterogeneous public health problem, it is also 
appropriate to consider patient preferences at the population level, particularly when 
considering priorities for research initiatives.154 There have been many studies of the patient 
experience in AF.155 There is a robust body of research regarding patient preferences with 
regard to OAC use, including patient self-monitoring of warfarin therapy.156,157 Less is 
known about patient preferences with regard to NOACs or rhythm control therapies, 
including catheter ablation. A systematic review of quality of life related to AF therapies 
demonstrated improvement with rate or rhythm control strategies but offered no further 
conclusions regarding patient decision-making about these strategies.158 Unfortunately, 
patient preference is seldom coded in systematic observational research regarding AF 
interventions.159 It is noteworthy that recent AF management guidelines systematically 
address the need to consider patient preferences.82
Patient-centered outcomes
In clinical trials, researchers often use a battery of quality of life indices (ie, SF-36, SF-12, 
EQOL) coupled with functional performance (ie, 6-minute hall walk test) as surrogate 
indicators of patient outcomes related to AF therapies. More recently, validated instruments 
of AF-related quality of life, like the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) 
questionnaire, have been incorporated.160 Moving forward, clinical studies should consider 
the broader impacts of rhythm control therapies on the patient's life experience, including 
emotional stress, financial costs, and impact on concomitant diagnoses (eg, stroke, HF). It is 
also important to understand patient access to AF care at both the individual and population 
levels.
Optimizing scientific and clinical yield from observational studies and registries
Large observational studies and multicenter registries play an important role in generating 
scientific and clinical knowledge at the population level. Registries can provide important 
insights into clinical epidemiology, disease presentation, risk factors for clinical events and 
disease progression, treatment utilization and patterns, and patient outcomes. Observational 
data and registries can include cohorts from large single health-care systems, multicenter 
studies, administrative claims databases, and national and international disease-based 
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registries (often under the leadership of a professional society). Although individual data 
repositories can be analyzed to answer a variety of clinical questions about the care of AF 
patients, these data sources may be even more valuable when merged. For example, analysis 
of a nationwide cohort of AF patients admitted with HF can help inform long-term outcomes 
when merged with longitudinal administrative claims data.161 As registries evolve to include 
EHRs and Internet or smartphone-based data capture systems, the possibilities grow. 
Smartphone diagnosis of PACs in patients enrolled in an existing outpatient cardiology 
registry could enable identification of risk for AF in “real time,” without creation of new 
study architecture or significant financial investment. Large registries can also provide an 
efficient platform for large, simple clinical trials.162 Using an existing registry to launch a 
clinical trial can help to identify patients, streamline enrollment, and minimize operational 
costs.
To create synergy between studies, the data collected must be compatible. Prior professional 
society statements have helped to define standard data elements in AF, including definitions 
of AF type.163,164 As technologies and clinical knowledge expand, these data definitions 
and standards will require updates and revision. We recommend that (1) continued data-
element definition and standardization are needed; (2) observational datasets should be 
linked when possible to maximize their scientific contributions; and (3) registries should be 
used as a platform to launch large, simple “real world” clinical trials.
Traditional large, high-quality epidemiologic datasets (Framingham Heart Study, the Multi-
Ethnic Study of Atherosclerosis, etc) have required the creation and maintenance of cohorts 
that are phenotyped in detail at study initiation and then followed at regular intervals. These 
cohorts have identified key cardiovascular risks, including risks factors for AF. An 
innovative approach to more efficiently collect observational data is the use of the Internet 
and/or mobile technologies to create decentralized cohorts followed remotely, using social 
media to recruit large numbers of participants. Smartphone use is becoming pervasive across 
all age and socioeconomic groups. With development of less expensive, noninvasive 
physiologic and behavior sensors, new paradigms for conducting clinical trials, registries, 
and cohort studies are being developed. Devices available today can track activity, sleep, 
BP, pulse oximetry, ECG, and weight using smartphones that can seamlessly and reliably 
capture and transmit data to central servers. The Health eHeart Study (http://www.health-
eheartstudy.org) is a study that has developed a large decentralized cardiovascular cohort in 
an attempt to collect “big data” to better predict, prevent, and treat cardiovascular diseases, 
including AF.
Use of “eRegistries” like the Health eHeart Study may reduce the costs of large-scale 
clinical research. Important features of this approach are (1) an online consent process that 
does not require an in-person visit, (2) an engaging interface, and (3) multiple mechanisms 
for interventions aimed at participant retention. This program has approval from the 
University of California San Francisco IRB, and participants are enrolled under their 
supervision, regardless of where the participant lives or receives health care. In addition to 
the possibility of performing registry-embedded clinical trials, e-registries also can utilize 
crowd-sourced research, in which patients or patient advocacy groups become more invested 
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in the research. The Health eHeart Study has collaborated with patient advocacy groups such 
as the American Heart Association and StopAfib to create the Health eHeart Alliance.
The emerging clinical research “fabric” will be woven from registry-driven trials that are 
conducted in the context of integrated health systems and powered by ubiquitous patient 
data from EHRs as well as “patient-centered” (or reported) data. This new construct for 
clinical research has the potential to enable trials to be initiated more quickly and conducted 
more efficiently, leveraging data already collected as part of routine care and monitoring. 
New initiatives putting these ideas into practice include the NIH Health Care Systems 
Collaboratory (http://nihcollaboratory.org)165 and PCORnet (http://pcornet.org/); they 
represent important avenues for future clinical AF research.
Highly developed registries supported by the ACC, AHA, ESC, and other global 
professional societies should be able to intersect with these resources to create a more 
efficient, high-throughput system.165 The Heart Rhythm Society and its partners are well 
positioned to make a significant contribution to this process by convening patients, 
providers, the NIH, and industry to assess the larger clinical trials portfolio, with the aim of 
applying system resources to the most important consensus priorities in AF.
Key research priorities
Evaluation of the causative factors involved in prefibrillatory/AF-contributory states
Given the frequency of AF and its cost to the worldwide health care systems, primary 
prevention of AF is a critical goal. Despite their importance, effective AF primary 
prevention strategies remain elusive. To explore, test, and refine AF prevention strategies, 
careful identification of at-risk patients is paramount. Multiple risk prediction schemes have 
been derived and validated through cohort and population studies, largely focusing on 
demographics, comorbidities, and physiologic measurements.53,54 Use of genetic 
approaches to identify individuals at risk for AF is promising but still remains challenging.51 
An alternative approach is the identification of high-risk electrophysiologic substrates. 
Several electrophysiologic substrates are known to be prefibrillatory or AF-contributory, and 
may help to evaluate primary prevention strategies and refine our understanding of the 
pathogenesis of incident AF.
Obesity, diabetes, hypertension, and sleep apnea are modifiable risk factors that may 
promote atrial structural remodeling and PAC burden that are strongly associated with AF 
risk and that warrant attention and remediation for primary and secondary prevention, both 
separately and in aggregate. As discussed in previous sections, PAC burden is associated 
with future risk of AF.10,141 Increased atrial conduction times and PR prolongation are also 
associated with increased risk of incident AF.51 Basic and translational studies that identify 
and study of the causative factors and mechanisms behind these AF-contributory states are 
needed. Large observational cohort studies may help to better define the risk and time course 
of developing AF in these contributory states. EHRs and health information technology may 
facilitate integration of traditional risk factors, cardiovascular imaging, biomarker data, and 
other physiologic measures with AF-contributory states to create novel, multimodal AF risk 
scores.
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Randomized primary prevention of AF in patients at high risk for developing AF
Despite significant interest and the obvious public health and economic benefits that would 
follow from the successful prevention of AF, there are no proven interventions for the 
primary prevention of AF. Most primary prevention studies to date have been post hoc 
analyses of RCTs conducted for other conditions and end-points. These studies are often 
limited to AF diagnosis by 12-lead ECG without more in-depth assessment of AF burden 
and frequently suffer from limited power. Best practice RCTs in patients with multiple risk 
factors for AF, including AF-contributory states, should be high priorities for government 
and nongovernmental funding agencies. Candidate interventions (Table 1) might include β-
adrenergic blockers, novel compounds such as HDAC43 and CaMKII17 inhibitors, statins or 
isoform-specific NADPH oxidase inhibitors,27 and autonomic modulation.
As suggested above, systematic longitudinal studies are also needed to evaluate the value of 
aggressively treating AF-related risk factors, including obesity, diabetes, hypertension, and 
sleep apnea, for the prevention of incident AF. Early identification and treatment of these 
conditions may help to limit atrial remodeling and the propensity to develop AF. Future 
clinical trials of primary prevention therapies will need to focus on patients at sufficient risk 
but should not be restrictive. Ideally, these trials would be large “simple” randomized trials, 
embedded in a professional society registry, and focused on effectiveness.
Advancing secondary AF prevention
Although primary prevention of AF cannot be overemphasized, the distinction between 
primary and secondary prevention is somewhat arbitrary. Development of AF and 
underlying disease progression represents a continuum.16 Therapeutic attempts to interrupt 
this continuum are important both for persons at risk for AF and those with recurrent AF. To 
improve the efficacy of secondary AF prevention, more focused efforts to address the 
modifiable risk AF factors (hypertension, obesity, diabetes, sleep disordered breathing) are 
needed, in addition to targeting the triggers and the anatomic/functional substrate for AF.
Integrating and coordinating the activity of HRS members and global 
collaborators
For the Heart Rhythm Society to have an enduring impact on scientific research focused on 
answering the most urgent questions concerning AF and stroke, it will be important to set up 
a structure that effectively harnesses the time and talents of HRS members and global 
partners. During the research forum, several possible strategies were discussed.
The first strategy was the development of a Heart Rhythm Trials network, patterned after the 
NIH-funded Cardiac Surgery or Heart Failure Trials networks. For such a proposal to be 
feasible, participants would need to prepare a multisite application with detailed plans for a 
series of compelling and feasible studies that the network would undertake, with sufficient 
evidence to support both the feasibility and the scientific and clinical benefit that would 
justify the creation of such a network. NIH resources are currently quite constrained, and 
significant costs are associated with developing the infrastructure needed to support these 
clinical trial networks.
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An alternative strategy would be one in which the HRS develops a mechanism to bring 
researchers together around specific research projects focused on AF and stroke. Once a 
compelling question is identified, researchers from various institutions can join together to 
craft and conduct the clinical trial. The Canadian Heart Rhythm Society has been very 
successful in utilizing such an approach throughout Canada to collaborate in an informal 
clinical trials network. Unlike a federally funded clinical trial network grant, this concept 
avoids the considerable costs of creating a large infrastructure to support a family of trials.
A third alternative to advance AF clinical science would be the development of a voluntary 
AF ablation registry. An initial attempt to accomplish this goal was undertaken by the Safety 
of Atrial Fibrillation Ablation Registry Initiative (SAFARI) working group. Although 
considerable progress was made, funding was never secured to launch this AF ablation 
registry. With increased awareness of the value of clinical registries, another effort to 
developing a voluntary AF ablation registry could be successful. This Research Forum 
recommends that the Heart Rhythm Society should develop a working group to focus on this 
issue.
Consensus top priorities for AF research
Based on reviews of existing epidemiologic trends, basic science, clinical outcomes, and 
unmet needs in clinical practice, the research committee and key stakeholders articulated top 
priorities for AF research that will advance progress toward the primary and secondary 
prevention of AF. Figure 4 summarizes our current research priorities; these can be divided 
into several key themes, including improving our understanding of the role of modifiable 
risk factors on AF pathophysiology and progression, improving risk stratification, and better 
understanding of current clinical outcomes. The focus on innovation in clinical research 
methods highlights the importance of changing the way we conduct clinical investigation. 
Improved clinical trial methods are needed in order to provide more relevant answers to 
clinical questions and in a more efficient and timely manner.
Top basic science/translational research priorities
1. Elucidate the mechanisms underlying ectopy originating from the PVs and other 
sources in pAF patients, and determine why this ectopy predominantly results in 
AF in older individuals.
2. Identify the genes, signaling pathways, and mechanisms by which genetic loci 
associated with AF risk impact atrial physiology, and evaluate the interaction of 
these pathways with modifiable risk factors.
3. Determine the stage(s) at which AF risk factor reduction (weight loss, BP 
management, sleep apnea, etc) can reverse atrial structural remodeling and/or 
conduction heterogeneity, and help to prevent (or slow the progression of) AF.
4. Develop new preventive treatments focused on key AF mechanisms (atrial ectopy, 
oxidant stress, proteostasis, fibrosis, etc) to enhance safety and efficacy.
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Top clinical research priorities
1. Develop and validate an AF risk score using developing and contemporary 
technologies, including genetic markers, electrocardiographic variables, biomarker 
data, imaging data, autonomic data, and AF-contributory states.
2. Perform RCTs of primary prevention strategies of AF in patients with high AF risk 
scores.
3. Establish new AF registries or utilize existing AF registries to launch large, simple, 
“real world” clinical trials.”
4. Use or create observational cohort studies to better define the risk and time course 
of developing AF in known AF-contributory states such as frequent PACs, 
prolonged atrial conduction time, and atrial flutter, and to discover new ones.
5. Develop novel social science approaches to enhance patient participation, 
engagement, and compliance in long-term preventive lifestyle modification studies.
6. Create an AF trials network to facilitate the conception,design, initiation, 
execution, and completion of innovative clinical trials designed address key clinical 
priorities,as defined by providers, patients, and payers.
Priorities that continue from the 2008 AF Prevention Report1
7. Continue to develop large animal models with spontaneous initiation of AF.
8. Continue to improve and validate noninvasive methods to image AF, to quantify LA 
fibrosis, and to image the brain (for AF/stroke risk stratification).
Conclusion
Despite continued improvements in the treatment of AF, effective methods for preventing 
AF remain elusive. Important targets for preventive therapy include both the processes 
underlying the development of triggers for AF and the substrate susceptible to AF. We need 
to better evaluate the impact of early treatment of known AF risk factors. Cellular and 
physiologic targets that are important areas of ongoing and future research include atrial 
ectopy, calcium handling, atrial fibrosis, atrial myocyte proteostasis, and oxidant stress. 
Similarly, research is needed in order to better understand how risk factor modification 
impacts future risk of AF, including treatment of hypertension, diabetes, obesity, HF, and 
sleep disordered breathing. Important clinical priorities include better methods of 
noninvasive atrial imaging and methods of atrial trigger and substrate modification, 
including advances in catheter ablation and novel drug therapies. Clinical research priorities 
are accompanied by important and needed changes in methodology. Incorporation of 
patient-centered outcomes, utilization of existing and emerging registries for the 
development and execution of large, real-world, and simple clinical trials, and the creation 
of an AF clinical trials network are among the important priorities. The growing prevalence 
of AF remains a daunting public health problem. The mindset of health care providers 
focused on primary AF prevention will need to change from the current focus on procedures 
on individual patients to a broader focus on the identification and treatment of risk factor 
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reduction in the population of the at-risk patients. Cooperation and collaboration between 
professional societies, practicing clinicians, clinical investigators, basic scientists, patient 
advocacy groups, funding agencies, government, industry, and health care systems will be 
paramount if we are to stem the tide of AF and reduce its associated morbidity and 
mortality.
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Abbreviations
ACEi angiotensin-converting enzyme inhibitor
AF atrial fibrillation
A-II angiotensin-II
ANP atrial natriuretic peptide
ARB angiotensin receptor blocker
BP blood pressure
BMI body mass index
BNP brain natriuretic peptide
CaMKII calmodulin-dependent kinase II
DAD delayed afterdepolari-zation
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EAD early afterdepolarization
ECM electrocardio-graphic mapping
EHR electronic health record
ET-1 endothelin-1
GGA geranyl-geranylacetone
GP ganglionated plexi
HDAC6 histone deacetylase-6
HF heart failure
HSP heat shock protein
LA left atrium
LAA left atrial appendage
LGE-CMR late gadolinium enhanced cardiac magnetic resonance imaging
LV left ventricle
MRI magnetic resonance imaging
NIH National Institutes of Health
NOAC non–vitamin K-dependent oral anticoagulant
NP natriuretic peptide
OAC oral anticoagulant
PAC premature atrial contraction
pAF paroxysmal atrial fibrillation
PV pulmonary vein
PVI pulmonary vein isolation
RAAS renin–angiotensin–aldosterone system
RCT randomized controlled trial
RSD renal sympathetic denervation
SDB sleep disordered breathing
SR sarcoplasmic reticulum
TGF transforming growth factor
TTR time in therapeutic range
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Figure 1. 
Overview of the proteostasis network, related signaling pathways, and modifiers. The 
physiologic and functional state of cells, including atrial myocytes, is related to proteome 
function, which is managed by the proteostasis network. The proteostasis network includes 
central pathways involved in the degradation of “old” proteins, the synthesis of new proteins 
within the endoplasmic reticulum (ER), and the folding and trafficking of native proteins. 
Central pathways regulated by signaling pathways that are activated during stresses such as 
AF include the heat shock factor 1-induced heat shock response, ER stress, the unfolded 
protein responses (UPR), activation of histone deacetylase 6-(HDAC6), and systemic 
inflammation. Genetic variants, caloric restriction, metabolic load, and physiologic stresses 
can modify the proteostasis network.
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Figure 2. 
Modifiable risk factors promote a substrate for AF. This figure illustrates the interactions of 
modifiable risk factors that lead to AF. Clinical and translational studies are needed to test 
the hypothesis that AF incidence and burden can be reduced by interventions that reduce the 
burden of patient-specific modifiable risk factors. Nonmodifiable risk factors (aging, 
genetics, etc) can further modulate the influence of the above risk factors on the 
development of AF.
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Figure 3. 
Mechanisms linking sleep disordered breathing (SDB) with risk of AF. Continuous positive 
airway pressure (CPAP) can help to reduce the burden of SDB and thus may be a useful tool 
in the prevention of AF, as well as the intermediate pathologic processes.
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Figure 4. 
Summary of the research targets and goals of the translational research cycle needed to 
systematically reduce the global incidence and burden of atrial fibrillation.
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Table 1
Pathways that might be targeted to advance AF prevention and treatment
Pathway Candidate approaches
Atrial ectopy Calcium-dependent calmodulin kinase II (CaMKII) inhibitors
Suppression of atrial myocyte oxidant production
Selective late sodium channel blockers
Modulation of ryanodine receptor oxidation/phosphorylation
Atrial fibrosis Inhibition of renin–angiotensin II–aldosterone, endothelin-1 and transforming growth factor-β 
signaling pathways
Modulation of fibroblast ion channels
Anti-inflammatory/antioxidant/antifibrotic drugs to attenuate fibroblast activation, proliferation and 
extracellular matrix accumulation
miRNA targeting of profibrotic signaling pathways
Proteostasis/microtubule modulation Modulation of heat shock protein/chaperone abundance
Modulation of proteosome activity
Suppression of atrial amyloid production/aggregation
Modulation of microtubule stability/subcellular targeting
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